technetium tc-99m mertiatide kit - Profile

What are the generic drug sources for technetium tc-99m mertiatide kit and what is the scope of patent protection?

Technetium tc-99m mertiatide kit is the generic ingredient in three branded drugs marketed by Curium, Medi-radiopharma, Sun Pharm Inds Inc, and Jubilant Draximage, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Summary for technetium tc-99m mertiatide kit

US Patents:	0
Tradenames:	3
Applicants:	4
NDAs:	4

US Patents and Regulatory Information for technetium tc-99m mertiatide kit

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990	AP	RX	Yes	Yes
Medi-radiopharma	TECHNETIUM TC99M MERTIATIDE KIT	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	206489-001	Feb 6, 2020	AP	RX	No	No
Sun Pharm Inds Inc	TECHNETIUM TC99M MERTIATIDE KIT	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	208994-001	Jul 12, 2019	AP	RX	No	No

Expired US Patents for technetium tc-99m mertiatide kit

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	TECHNESCAN MAG3	technetium tc-99m mertiatide kit	INJECTABLE;INJECTION	019882-001	Jun 15, 1990

Technetium Tc-99m Mertiatide Kit: Investment Fundamentals Analysis

Last updated: February 19, 2026

Technetium Tc-99m Mertiatide Kit is a radiopharmaceutical used for diagnostic imaging, specifically for renal imaging and assessment of renal function. Its market position is influenced by its efficacy, regulatory status, patent landscape, and the competitive environment of diagnostic imaging agents.

What is Technetium Tc-99m Mertiatide Kit?

Technetium Tc-99m Mertiatide Kit is an injectable diagnostic agent. The active component is mertiatide, which is radiolabeled with Technetium-99m (Tc-99m). Tc-99m is a gamma-emitting radioisotope with a half-life of approximately 6 hours, making it suitable for nuclear medicine imaging. Mertiatide is a chelating agent that binds Tc-99m and facilitates its excretion by the kidneys, allowing for imaging of renal structure and function. The kit formulation allows for on-site radiolabeling of the mertiatide with Tc-99m pertechnetate, a commonly available radiotracer in nuclear medicine departments.

Key characteristics:

• Mechanism of Action: Mertiatide binds to Technetium-99m, forming a complex that is rapidly cleared by the kidneys. This complex is taken up by the renal tubules and excreted into the urine, enabling visualization of the renal parenchyma, collecting system, and ureters.
• Indications: Primarily used for renal imaging to assess renal perfusion, differentiate between renal parenchymal disease and obstruction, evaluate renal transplant function, and assess renal artery stenosis in conjunction with other imaging techniques.
• Administration: Intravenous injection.
• Imaging Modality: Single-photon emission computed tomography (SPECT) and planar scintigraphy.

What is the Regulatory Status and Approval History?

The regulatory approval of Technetium Tc-99m Mertiatide Kit is critical for its market access and commercial viability. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) review the safety and efficacy of such agents.

FDA Approval and History:

• The FDA approved Technetium Tc-99m Mertiatide (also known by brand names such as TechneLite Tc-99m Mertiatide) for use in the United States.
• The initial approval for Technetium Tc-99m Mertiatide was granted in the late 1990s and early 2000s, with subsequent supplemental approvals for updated indications or manufacturing processes.
• The product's availability is tied to the manufacturing and distribution of Tc-99m itself, which is derived from Molybdenum-99 (Mo-99). Global supply chain disruptions for Mo-99 can impact the availability of Tc-99m-labeled radiopharmaceuticals.

EMA Approval and History:

• In Europe, Technetium Tc-99m Mertiatide has undergone similar regulatory scrutiny and approval processes through the EMA.
• Marketing authorization is country-specific within the European Union, often following a centralized or decentralized procedure.

Recent Regulatory Developments:

• As of late 2023, there are no major recent FDA or EMA recalls or significant safety warnings specifically impacting Technetium Tc-99m Mertiatide Kit that would fundamentally alter its current market position, beyond general radiopharmaceutical handling and safety protocols. However, ongoing pharmacovigilance monitoring is standard for all approved drugs.

What is the Patent Landscape for Technetium Tc-99m Mertiatide Kit?

The patent landscape for Technetium Tc-99m Mertiatide Kit is a key factor in determining market exclusivity and the potential for generic competition. Patents typically cover the composition of matter, method of use, and manufacturing processes.

• Original Patents: Patents covering the initial development and composition of mertiatide and its use in Tc-99m radiolabeling have likely expired. The original patent filing dates for mertiatide-based imaging agents date back to the 1980s and 1990s. For example, U.S. Patent 4,806,349, related to diamine-monoamine-polyamine-polycarboxylate chelating agents for radiometal labeling, was filed in the mid-1980s, indicating the foundational intellectual property predates current market availability of some products.
• Expired Patents: Patents that provided initial market exclusivity for Technetium Tc-99m Mertiatide have largely expired, opening the door for potential generic or biosimilar competition, although the complexity and specialized nature of radiopharmaceuticals can limit generic entry.
• Evergreening Strategies: Manufacturers may pursue patents on new formulations, delivery methods, or specific clinical applications to extend market exclusivity. However, detailed public patent databases do not currently indicate significant ongoing patent protection for novel formulations or uses of Technetium Tc-99m Mertiatide Kit that would provide substantial future market exclusivity beyond its established indications.
• Generic Entry: The absence of strong, current patents may allow for the development of generic versions of Technetium Tc-99m Mertiatide Kit, potentially increasing price competition. However, regulatory hurdles for radiopharmaceuticals, including manufacturing site inspections and bioequivalence studies (where applicable), remain significant.

What are the Competitive Landscape and Market Dynamics?

The market for diagnostic imaging agents for renal function assessment is competitive, with several agents and modalities vying for clinical use. Technetium Tc-99m Mertiatide Kit competes against other Tc-99m based agents and alternative imaging technologies.

Direct Competitors (Tc-99m based renal imaging agents):

• Technetium Tc-99m Dimercaptosuccinic Acid (DMSA): Used for static renal imaging, particularly to assess renal scarring in pyelonephritis. DMSA is retained in the renal cortex, providing functional and morphological information about the parenchyma.
• Technetium Tc-99m Glucaric acid: Another agent investigated for renal imaging, though less widely adopted than DMSA or mertiatide.
• Technetium Tc-99m Succimer (DMSA analog): Similar to DMSA in its use for cortical imaging.

Indirect Competitors (Alternative Modalities):

• Ultrasound: A widely available, non-ionizing imaging technique that can assess renal size, structure, and blood flow (Doppler ultrasound). It is often the first-line imaging modality for many renal conditions.
• Computed Tomography (CT): Offers detailed anatomical imaging and can assess renal perfusion and excretory function with contrast agents. CT urography is used for evaluating the collecting system.
• Magnetic Resonance Imaging (MRI): Provides excellent soft tissue contrast and can assess renal perfusion and function, particularly useful in patients with contraindications to iodinated contrast agents used in CT. MR urography is an alternative to CT urography.
• Contrast-enhanced X-ray: Intravenous urography (IVU) using iodinated contrast agents was historically used but has largely been replaced by CT and MRI for detailed renal evaluation due to superior anatomical detail and lower radiation dose with CT.

Market Dynamics:

• Shifting Preferences: There is a trend towards minimizing radiation exposure where possible, which may favor non-ionizing modalities like ultrasound and MRI.
• Cost-Effectiveness: The cost of the agent, disposables, and imaging equipment plays a significant role in clinical adoption. Tc-99m agents are generally cost-effective for routine renal imaging.
• Availability of Mo-99/Tc-99m Generators: The consistent and reliable supply of Mo-99, the parent isotope for Tc-99m, is crucial. Global shortages of Mo-99 can impact the availability of all Tc-99m radiopharmaceuticals, including Technetium Tc-99m Mertiatide Kit.
• Clinical Expertise and Infrastructure: The use of Tc-99m agents requires specialized nuclear medicine equipment and trained personnel, which may be a limiting factor in some healthcare settings.

What are the Key Market Drivers and Restraints?

Several factors influence the demand and adoption of Technetium Tc-99m Mertiatide Kit.

Market Drivers:

• Prevalence of Renal Diseases: Increasing incidence of chronic kidney disease (CKD), hypertension, diabetes, and urinary tract infections contributes to the demand for renal diagnostic tools.
• Advancements in Radiopharmacy: Development of more stable and effective Tc-99m formulations can enhance diagnostic accuracy.
• Cost-Effectiveness of SPECT/Planar Imaging: Compared to some advanced CT or MRI protocols, nuclear medicine imaging with Tc-99m agents can offer a cost-effective option for specific diagnostic questions related to renal function.
• Established Clinical Protocols: Technetium Tc-99m Mertiatide has established protocols and a history of use, providing familiarity among nuclear medicine physicians.
• Limited Radiation Dose: Tc-99m has a relatively short half-life and emits gamma rays, allowing for relatively low radiation doses compared to some other imaging modalities, particularly when compared to older CT techniques.

Market Restraints:

• Competition from Advanced Imaging Modalities: MRI and CT offer superior anatomical resolution for many renal pathologies, potentially reducing the need for functional imaging with Tc-99m agents in certain cases.
• Mo-99/Tc-99m Supply Chain Vulnerability: Dependence on Mo-99 production facilities makes the entire Tc-99m radiopharmaceutical market susceptible to supply disruptions, impacting availability and potentially driving up costs.
• Radiation Exposure Concerns: Although relatively low, any radiation exposure can be a concern for some patients and clinicians, particularly in pediatric populations or for serial imaging.
• Development of Novel Diagnostic Agents: Research into new diagnostic agents, including PET tracers or novel functional MRI techniques, could offer improved diagnostic capabilities.
• Increasing Regulatory Scrutiny: Stringent regulatory requirements for radiopharmaceutical manufacturing and quality control can increase the cost of production and market entry for new or generic products.

What are the Financial Projections and Investment Considerations?

Forecasting the financial performance of Technetium Tc-99m Mertiatide Kit requires analysis of its current market share, growth trajectory, and potential threats. Due to the mature nature of established radiopharmaceuticals and the competitive landscape, significant rapid growth is unlikely.

• Market Size and Growth: The global market for radiopharmaceuticals used in diagnostic imaging is substantial, with renal agents forming a segment of this. The overall market for Tc-99m agents is projected to grow at a modest compound annual growth rate (CAGR) of 3-5% over the next five years, driven by aging populations and increasing healthcare access in emerging economies. However, specific growth for Technetium Tc-99m Mertiatide Kit will be influenced by its direct competition and the adoption rates of alternative technologies.
• Pricing and Profitability: Pricing is influenced by manufacturing costs, regulatory compliance, competition, and healthcare reimbursement policies. Profit margins can be stable for established products with efficient supply chains, but are vulnerable to raw material price fluctuations and generic pressure.
• Investment Risks:
  • Supply Chain Risk: Disruptions in Mo-99 supply can severely impact revenue.
  • Technological Obsolescence: The development of superior imaging technologies could marginalize the need for Technetium Tc-99m Mertiatide Kit.
  • Generic Competition: Expired patents increase the risk of market share erosion due to lower-priced generic alternatives.
  • Reimbursement Changes: Shifts in healthcare payer policies or reimbursement rates for nuclear medicine procedures can affect profitability.
• Investment Opportunities:
  • Niche Applications: Companies with strong positions in specific, underserved renal imaging applications where Technetium Tc-99m Mertiatide Kit excels may represent stable investment opportunities.
  • Supply Chain Optimization: Companies focused on securing and optimizing the Mo-99/Tc-99m supply chain may offer indirect investment benefits.
  • Emerging Markets: Expansion of nuclear medicine infrastructure in developing countries could provide growth opportunities.

Key Financial Indicators:

• Revenue: Dependent on unit sales volume and average selling price. Current revenue streams are likely stable but not high-growth.
• Cost of Goods Sold (COGS): Includes raw materials (e.g., Tc-99m generators, mertiatide precursor), manufacturing labor, and quality control.
• Gross Margin: Reflects the profitability of the product before operating expenses.
• Operating Expenses: Include R&D, sales and marketing, and administrative costs.

Key Takeaways

• Technetium Tc-99m Mertiatide Kit is a diagnostic radiopharmaceutical for renal imaging with an established, but mature, market position.
• Original patent protection has largely expired, increasing the potential for generic competition, although regulatory barriers remain significant for radiopharmaceuticals.
• The competitive landscape includes other Tc-99m renal agents and alternative imaging modalities such as ultrasound, CT, and MRI, which offer superior anatomical detail.
• Market drivers include the prevalence of renal diseases and the cost-effectiveness of SPECT imaging, while restraints are posed by competition, supply chain vulnerabilities for Tc-99m, and radiation concerns.
• Investment considerations are characterized by stable but not high-growth revenue potential, with significant risks related to supply chain disruptions and technological obsolescence.

FAQs

1. What is the primary clinical advantage of Technetium Tc-99m Mertiatide Kit over other Tc-99m renal agents like DMSA? Technetium Tc-99m Mertiatide Kit is primarily used for dynamic renal imaging to assess renal perfusion and excretion, differentiating functional tissue from scar or obstruction, and evaluating renal vascularity. DMSA, conversely, is used for static imaging to assess cortical uptake and identify focal parenchymal defects like scars.
2. How susceptible is the market for Technetium Tc-99m Mertiatide Kit to disruptions in the Molybdenum-99 (Mo-99) supply chain? The market is highly susceptible. Mo-99 is the parent isotope for Technetium-99m (Tc-99m), the radioisotope used to label mertiatide. Any reduction in Mo-99 availability directly limits the production and distribution of all Tc-99m radiopharmaceuticals, including Technetium Tc-99m Mertiatide Kit.
3. What is the typical half-life of Technetium-99m and how does this impact its use in diagnostic imaging? Technetium-99m has a half-life of approximately 6 hours. This relatively short half-life is advantageous as it allows for effective imaging within several hours of administration while minimizing the radiation dose to the patient after the scan.
4. Are there specific patient populations for whom Technetium Tc-99m Mertiatide Kit imaging is preferred or contra-indicated? It is preferred for assessing functional renal parameters where anatomical detail is less critical than dynamic uptake and excretion. Contra-indications are generally limited to known hypersensitivity to the components. However, considerations for radiation exposure may arise in pregnant or breastfeeding patients, and in pediatric populations where other modalities with no ionizing radiation may be favored if clinically appropriate.
5. Beyond renal imaging, are there any other diagnostic applications for Technetium Tc-99m Mertiatide Kit? While its primary and most established indication is for renal imaging, mertiatide has been explored for other renally excreted pathways or in combination with other imaging techniques. However, its widespread clinical use and regulatory approvals are predominantly for renal scintigraphy and SPECT imaging.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] European Medicines Agency. (n.d.). European Register of Medicines in Human Use. Retrieved from https://www.ema.europa.eu/en/medicines/human [3] U.S. Patent 4,806,349. (1989). Diamine-monoamine-polyamine-polycarboxylate chelating agents for radiometal labeling. [4] Global Market Insights. (2023). Radiopharmaceutical Market Size, Share & Industry Analysis, By Type (Diagnostic, Therapeutic), By Radioisotope, By Application (Oncology, Cardiology, Neurology, Gastroenterology, Nephrology, Endocrinology, Others), By End-User (Hospitals, Diagnostic Centers, Research Institutions), And Regional Forecasts 2023 – 2032.